Betting protein degradation will beat mere inhibition
This article was originally published in Start Up
Arvinas Inc. believes it has found a better approach to drug development: instead of inhibiting proteins, the start-up aims to degrade and remove them from the system entirely. The company will exploit two technology platforms developed at Yale University, both of which provide ways of marking specific proteins for destruction by normal cellular mechanisms.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.